$3.36
+0.04 (+1.36%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IXHL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 4 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC) · FINRA short interest 9.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.NCT07635563Change in AHI4 at the end of each treatment period compared to baselineRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide, Placebo: Negative control | Obstructive Sleep Apnea (OSA) | 120 | Apr 2027 | ≤ 254 d | 2026-08-13 |
| RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSANCT06146101Change in apnea-hypopnea index (AHI)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Completed | Drug: IHL-42X Low Dose, IHL-42X High Dose, Placebo, IHL-42X (Optimal Dose), Dronabinol, Acetazolamide, Placebo | Obstructive Sleep Apnea | 121 | 2025-05-20actual | — | 2026-07-27 |
| Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid ArthritisNCT05942911Change in pain and functionRandomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Recruitment challenges | Drug: IHL-675A, Cannabidiol, Hydroxychloroquine, Placebo | Rheumatoid Arthritis | 20 | 2024-10-28actual | — | 2026-03-27 |
| Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference DrugsNCT05857384Bioavailability of IHL-42XRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: IHL42X, Acetazolamide 250 MG, Dronabinol 2.5 MG | Obstructive Sleep Apnea | 125 | 2024-07-31actual | — | 2025-01-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19